News Ipilimumab in Uveal Melanoma: Long-Lasting Responses in 25% by Medscape • 2014/12/02 • 0 Comments The first trial of ipilimumab in patients with uveal melanoma has shown some long-lasting responses in a patient population with poor prognosis. Medscape Medical News Full Story →